These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

812 related articles for article (PubMed ID: 29480353)

  • 21. Antemortem CSF A
    Baiardi S; Abu-Rumeileh S; Rossi M; Zenesini C; Bartoletti-Stella A; Polischi B; Capellari S; Parchi P
    Ann Clin Transl Neurol; 2019 Feb; 6(2):263-273. PubMed ID: 30847359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma β-amyloid in Alzheimer's disease and vascular disease.
    Janelidze S; Stomrud E; Palmqvist S; Zetterberg H; van Westen D; Jeromin A; Song L; Hanlon D; Tan Hehir CA; Baker D; Blennow K; Hansson O
    Sci Rep; 2016 May; 6():26801. PubMed ID: 27241045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease.
    Eruysal E; Ravdin L; Zhang C; Kamel H; Iadecola C; Ishii M
    J Alzheimers Dis; 2023; 91(3):1073-1083. PubMed ID: 36565112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.
    Tzen KY; Yang SY; Chen TF; Cheng TW; Horng HE; Wen HP; Huang YY; Shiue CY; Chiu MJ
    ACS Chem Neurosci; 2014 Sep; 5(9):830-6. PubMed ID: 25054847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.
    Kokkinou M; Beishon LC; Smailagic N; Noel-Storr AH; Hyde C; Ukoumunne O; Worrall RE; Hayen A; Desai M; Ashok AH; Paul EJ; Georgopoulou A; Casoli T; Quinn TJ; Ritchie CW
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010945. PubMed ID: 33566374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
    J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform.
    Agnello L; Giglio RV; Del Ben F; Piccoli T; Colletti T; Scazzone C; Lo Sasso B; Ciaccio AM; Gambino CM; Salemi G; Ciaccio M
    Sci Rep; 2024 Jul; 14(1):16084. PubMed ID: 38992063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.
    Sagare AP; Deane R; Zetterberg H; Wallin A; Blennow K; Zlokovic BV
    J Alzheimers Dis; 2011; 24(1):25-34. PubMed ID: 21157031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms.
    Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer's disease.
    Verde F; Milone I; Dubini A; Colombrita C; Perego A; Solca F; Maranzano A; Ciusani E; Poletti B; Ratti A; Torresani E; Silani V; Ticozzi N
    Neurol Sci; 2023 Sep; 44(9):3287-3290. PubMed ID: 37284933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma amyloid beta levels and platelet mitochondrial respiration in patients with Alzheimer's disease.
    Fišar Z; Jirák R; Zvěřová M; Setnička V; Habartová L; Hroudová J; Vaníčková Z; Raboch J
    Clin Biochem; 2019 Oct; 72():71-80. PubMed ID: 30954436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V; Fandos N; Canudas J; Insua D; Casabona D; Lacosta AM; Montañés M; Pesini P; Sarasa M
    J Alzheimers Dis; 2016 Sep; 54(2):751-62. PubMed ID: 27567833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
    West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE
    Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral glucose loading modulates plasma β-amyloid level in alzheimer's disease patients: potential diagnostic method for Alzheimer's disease.
    Takeda S; Sato N; Uchio-Yamada K; Yu H; Moriguchi A; Rakugi H; Morishita R
    Dement Geriatr Cogn Disord; 2012; 34(1):25-30. PubMed ID: 22889768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease.
    Dorey A; Perret-Liaudet A; Tholance Y; Fourier A; Quadrio I
    Front Neurol; 2015; 6():247. PubMed ID: 26640457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.